Related Experiment Videos
Limitations in usefulness of single dose intermediate acting insulin: a rapid response pattern in some type I
Ten Type I insulin-dependent diabetics who were receiving single daily injections of intermediate acting insulin were studied to assess time-response characteristics of this therapy on 24-hour profiles of both glucose and free insulin. Nine of ten patients had undetectable postprandial levels of C-peptide. All patients had insulin antibodies typical of chronically treated Type I diabetes. Mean peak free insulin levels occurred four hours post injection with free insulin rising from 12.3 +/- 1.6 microU/ml to 26.5 +/- 1.4 microU/ml; p less than 0.01. The glucose nadir for the 24-hour profile also occurred at four hours after injection with glucose declining from 199 +/- 29 mg/dl fasting to 155 +/- 5 mg/dl; p less than 0.05. There was significant negative correlation between mean glucose and free insulin throughout the first six hours after insulin injection (r = -0.74; p less than 0.02); no correlation occurred 8 to 12 hours post injection. Two of the ten patients had hypoglycemic symptoms within four hours after their morning insulin. Although free insulin levels remained above basal for 20 hours, single dose intermediate insulin therapy never really controlled postprandial glucose levels after breakfast or lunch. These data suggest there may be limitations in managing Type I diabetics with single dose intermediate insulin. Furthermore, some patients on intermediate acting insulin may have a more rapid than anticipated maximal hypoglycemic response, often within four hours.
Ten Type I insulin-dependent diabetics who were receiving single daily injections of intermediate acting insulin were studied to assess time-response characteristics of this therapy on 24-hour profiles of both glucose and free insulin. Nine of ten patients had undetectable postprandial levels of C-peptide. All patients had insulin antibodies typical of chronically treated Type I diabetes. Mean peak free insulin levels occurred four hours post injection with free insulin rising from 12.3 +/- 1.6 microU/ml to 26.5 +/- 1.4 microU/ml; p less than 0.01. The glucose nadir for the 24-hour profile also occurred at four hours after injection with glucose declining from 199 +/- 29 mg/dl fasting to 155 +/- 5 mg/dl; p less than 0.05. There was significant negative correlation between mean glucose and free insulin throughout the first six hours after insulin injection (r = -0.74; p less than 0.02); no correlation occurred 8 to 12 hours post injection. Two of the ten patients had hypoglycemic symptoms within four hours after their morning insulin. Although free insulin levels remained above basal for 20 hours, single dose intermediate insulin therapy never really controlled postprandial glucose levels after breakfast or lunch. These data suggest there may be limitations in managing Type I diabetics with single dose intermediate insulin. Furthermore, some patients on intermediate acting insulin may have a more rapid than anticipated maximal hypoglycemic response, often within four hours.